Stock of the Day

Alnylam Pharmaceuticals (ALNY)

$303.57

-$4.43 (-1.4%)

Market Cap: $39.83B

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

• The company reported a significant revenue increase of over 20% compared to the same quarter last year, indicating strong growth potential.
• Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, with target prices suggesting substantial upside from the current stock price of around $304.86.
• Institutional investors hold a large majority of the company's stock, which can indicate confidence in the company's future performance.
• The company is focused on innovative therapeutics based on ribonucleic acid interference, positioning it well in the biopharmaceutical market.
• Recent analyst forecasts suggest that the company is expected to continue its growth trajectory, with projections for future earnings improving.

Alnylam Pharmaceuticals Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

• The company reported a loss of ($0.44) earnings per share, which was worse than analysts' expectations, raising concerns about profitability.
• Despite revenue growth, the company is still projected to have negative earnings for the current fiscal year, which may deter risk-averse investors.
• There is a relatively high debt-to-equity ratio, which could indicate financial risk if the company faces challenges in generating revenue.
• One investment analyst has rated the stock with a sell rating, suggesting some skepticism about its future performance.
• The stock has shown volatility, with a significant range in its twelve-month performance, which may be a concern for investors looking for stability.

Recent News

• Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 19,297 Shares of Stock (insidertrades.com)
• Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright (insidermonkey.com)